Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Commentary

Direct-acting Antivirals for Hepatitis C and Implication for Community Pharmacy Practice

Author(s): Sara McEntee, Yifei Liu*, Tahar Mahmoudi, Kathryn Oliver and Chad Cadwell

Volume 29, Issue 25, 2023

Published on: 28 August, 2023

Page: [1967 - 1970] Pages: 4

DOI: 10.2174/1381612829666230816145931

Price: $65

Abstract

The treatment options for hepatitis C have undergone noteworthy advancements since direct-acting antivirals (DAAs) were introduced. The selection of a DAA therapy depends on the patient’s genotype, treatment history, concomitant comorbidities, and concurrent medications. Pharmacists have a pivotal role in providing clarification and recommendations in selecting appropriate, individualized DAAs for patients. This commentary aims to (1) provide an overview of DAAs on the market for hepatitis C, and (2) describe the implication for the care of patients with hepatitis C in a community pharmacy. Community pharmacists can establish a workflow to recommend appropriate DAA therapy, identify drug interactions, and improve medication adherence and compliance with lab appointments.

« Previous Next »
[1]
McHutchison JG, Bacon BR, Owens GS. Making it happen: Managed care considerations in vanquishing hepatitis C. Am J Manag Care 2007; 13 (Suppl. 12): S327-36.
[PMID: 18095781]
[2]
The Centers for Disease Control and Prevention Hepatitis C Surveillance 2020. Available from: www.cdc.gov/hepatitis/statistics/2020surveillance/hepatitis-c.htm(Accessed January 6, 2023).
[3]
McHutchison JG, Bacon BR. Chronic hepatitis C: An age wave of disease burden. Am J Manag Care 2005; 11(10): S286-95.
[PMID: 16232012]
[4]
Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000; 132(4): 296-305.
[http://dx.doi.org/10.7326/0003-4819-132-4-200002150-00008] [PMID: 10681285]
[5]
World Health Organization Hepatitis C Available from: www.who.int/news-room/fact-sheets/detail/hepatitis-c
[6]
WHO Global Hepatitis Report 2017. 2017. Available fromhttps://www.who.int/publications/i/item/9789241565455
[7]
American Association for the Study of Liver Diseases and the Infectious Diseases Society of America HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C Available from:www.hcvguidelines.org(Accessed February 3, 2023)
[8]
Bukh J, Miller R, Purcell R. Genetic heterogeneity of hepatitis C virus: Quasispecies and genotypes. Semin Liver Dis 1995; 15(1): 41-63.
[http://dx.doi.org/10.1055/s-2007-1007262] [PMID: 7597443]
[9]
Chiu WN, Hung CH, Lu SN, et al. Real‐world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan. J Viral Hepat 2020; 27(9): 866-72.
[http://dx.doi.org/10.1111/jvh.13305] [PMID: 32343472]
[10]
McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339(21): 1485-92.
[http://dx.doi.org/10.1056/NEJM199811193392101] [PMID: 9819446]
[11]
Sarin SK, Kumar CKN. Treatment of patients with genotype 3 chronic hepatitis C- current and future therapies. Liver Int 2012; 32 (Suppl. 1): 141-5.
[http://dx.doi.org/10.1111/j.1478-3231.2011.02715.x] [PMID: 22212585]
[12]
McCombs J, Matsuda T, Tonnu-Mihara I, et al. The risk of long-term morbidity and mortality in patients with chronic hepatitis C: Results from an analysis of data from a Department of Veterans Affairs Clinical Registry. JAMA Intern Med 2014; 174(2): 204-12.
[http://dx.doi.org/10.1001/jamainternmed.2013.12505] [PMID: 24193887]
[13]
Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015; 373(27): 2608-17.
[http://dx.doi.org/10.1056/NEJMoa1512612] [PMID: 26575258]
[14]
Mohammad RA, Bulloch MN, Chan J, et al. Provision of clinical pharmacist services for individuals with chronic hepatitis C viral infection. Pharmacotherapy 2014; 34(12): 1341-54.
[http://dx.doi.org/10.1002/phar.1512] [PMID: 25359244]
[15]
Aghemo A, De Francesco R. New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology 2013; 58(1): 428-38.
[http://dx.doi.org/10.1002/hep.26371] [PMID: 23467911]
[16]
Casey LC, Lee WM. Hepatitis C therapy update. Curr Opin Gastroenterol 2012; 28(3): 188-92.
[http://dx.doi.org/10.1097/MOG.0b013e3283528e1e] [PMID: 22476156]
[17]
Gilead Sciences, Inc. Harvoni® package insert Foster City, CA 2015. Available from:https://hcp.harvoni.com/
[18]
Merck & Co Inc Zepatier® package insert Whitehouse Station, NJ 2016. Available from:https://www.merck.com/product/usa/pi_circulars/z/zepatier/zepatier_pi.pdf
[19]
Gilead Sciences, Inc. Inc Epclusa® package insert Foster City, CA 2016. Available from:https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208341s000lbl.pdf
[20]
AbbVie, Inc. Mavyret® package insert North Chicago, IL 2017. Available from:https://clinicaltrials.gov/ct2/results?cond=Melanoma&term=SiRNA&cntry=&state=&city=&dist=
[21]
Gilead Sciences, Inc. Vosevi® package insert Foster City, CA 2017. Available from:https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209195s000lbl.pdf
[22]
Dick TB, Lindberg LS, Ramirez DD, Charlton MR. A clinician’s guide to drug‐drug interactions with direct‐acting antiviral agents for the treatment of hepatitis C viral infection. Hepatology 2016; 63(2): 634-43.
[http://dx.doi.org/10.1002/hep.27920] [PMID: 26033675]
[23]
Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010; 138(2): 447-62.
[http://dx.doi.org/10.1053/j.gastro.2009.11.055] [PMID: 20006612]
[24]
Wyles DL, Luetkemeyer AF. Understanding hepatitis c virus drug resistance: Clinical implications for current and future regimens. Top Antivir Med 2017; 25(3): 103-9.
[PMID: 28820725]
[25]
Hill A, Khoo S, Fortunak J, Simmons B, Ford N. Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clin Infect Dis 2014; 58(7): 928-36.
[http://dx.doi.org/10.1093/cid/ciu012] [PMID: 24399087]
[26]
Roebuck MC. Impact of direct-acting antiviral use for chronic hepatitis C on health care costs in medicaid: Economic model update. Am J Manag Care 2022; 28(12): 630-1.
[http://dx.doi.org/10.37765/ajmc.2022.89273] [PMID: 36525655]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy